Experts are excitedly focused on retatrutide, a novel treatment developed by Eli Lilly, as a possible step in physique reduction . Distinct from many existing approaches, retatrutide is a double -action receptor targeting simultaneously GLP-1 and GIP, chemicals that influence satiety and blood suga